[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610456":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":203,"collaborators":25,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":25,"eligibilityCriteria":211,"healthyVolunteers":207,"sex":212,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":25,"studyType":218,"phases":219,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},{"fullName":5,"class":6},"Neurocrine Biosciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NBI-1117568","EXPERIMENTAL","All participants will receive NBI-1117568 during the Open-label Stabilization Period, then will be randomized to receive NBI-1117568 during the Double-blind Treatment Period.",[13],"Drug: NBI-1117568",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","All participants will receive NBI-1117568 during the Open-label Stabilization Period, then will be randomized to receive placebo matching NBI-1117568 during the Double-blind Treatment Period.",[13,19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Oral capsules",[9,15],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":5,"role":31},"Clinical Development Lead","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":25,"email":37},"Neurocrine Medical Information Call Center","CONTACT","1-877-641-3461","medinfo@neurocrine.com",[39,53,61,69,77,85,93,102,110,118,123,131,138,147,156,165,174,181,186,194],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":25},"Neurocrine Clinical Site","RECRUITING","Garden Grove","California","92845","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.94145,33.77391,{"lat":51,"lon":50},{"facility":40,"status":41,"city":54,"state":43,"zip":55,"country":45,"countryCode":46,"cosmosGeoPoint":56,"geoPoint":60,"contacts":25},"La Habra","90631",{"type":48,"coordinates":57},[58,59],-117.94617,33.93196,{"lat":59,"lon":58},{"facility":40,"status":41,"city":62,"state":43,"zip":63,"country":45,"countryCode":46,"cosmosGeoPoint":64,"geoPoint":68,"contacts":25},"Lemon Grove","91945",{"type":48,"coordinates":65},[66,67],-117.03142,32.74255,{"lat":67,"lon":66},{"facility":40,"status":41,"city":70,"state":43,"zip":71,"country":45,"countryCode":46,"cosmosGeoPoint":72,"geoPoint":76,"contacts":25},"Oceanside","92056",{"type":48,"coordinates":73},[74,75],-117.37948,33.19587,{"lat":75,"lon":74},{"facility":40,"status":41,"city":78,"state":43,"zip":79,"country":45,"countryCode":46,"cosmosGeoPoint":80,"geoPoint":84,"contacts":25},"Torrance","90504",{"type":48,"coordinates":81},[82,83],-118.34063,33.83585,{"lat":83,"lon":82},{"facility":40,"status":41,"city":86,"state":43,"zip":87,"country":45,"countryCode":46,"cosmosGeoPoint":88,"geoPoint":92,"contacts":25},"West Hills","91307",{"type":48,"coordinates":89},[90,91],-118.64398,34.19731,{"lat":91,"lon":90},{"facility":40,"status":41,"city":94,"state":95,"zip":96,"country":45,"countryCode":46,"cosmosGeoPoint":97,"geoPoint":101,"contacts":25},"Hollywood","Florida","33024",{"type":48,"coordinates":98},[99,100],-80.14949,26.0112,{"lat":100,"lon":99},{"facility":40,"status":41,"city":103,"state":95,"zip":104,"country":45,"countryCode":46,"cosmosGeoPoint":105,"geoPoint":109,"contacts":25},"Maitland","32751",{"type":48,"coordinates":106},[107,108],-81.36312,28.62778,{"lat":108,"lon":107},{"facility":40,"status":41,"city":111,"state":95,"zip":112,"country":45,"countryCode":46,"cosmosGeoPoint":113,"geoPoint":117,"contacts":25},"Miami","33122",{"type":48,"coordinates":114},[115,116],-80.19366,25.77427,{"lat":116,"lon":115},{"facility":40,"status":41,"city":111,"state":95,"zip":119,"country":45,"countryCode":46,"cosmosGeoPoint":120,"geoPoint":122,"contacts":25},"33155",{"type":48,"coordinates":121},[115,116],{"lat":116,"lon":115},{"facility":40,"status":41,"city":124,"state":95,"zip":125,"country":45,"countryCode":46,"cosmosGeoPoint":126,"geoPoint":130,"contacts":25},"Tampa","33629",{"type":48,"coordinates":127},[128,129],-82.45843,27.94752,{"lat":129,"lon":128},{"facility":40,"status":41,"city":132,"state":95,"zip":96,"country":45,"countryCode":46,"cosmosGeoPoint":133,"geoPoint":137,"contacts":25},"West Palm Beach",{"type":48,"coordinates":134},[135,136],-80.05337,26.71534,{"lat":136,"lon":135},{"facility":40,"status":41,"city":139,"state":140,"zip":141,"country":45,"countryCode":46,"cosmosGeoPoint":142,"geoPoint":146,"contacts":25},"Atlanta","Georgia","30318",{"type":48,"coordinates":143},[144,145],-84.38798,33.749,{"lat":145,"lon":144},{"facility":40,"status":41,"city":148,"state":149,"zip":150,"country":45,"countryCode":46,"cosmosGeoPoint":151,"geoPoint":155,"contacts":25},"Boston","Massachusetts","02116",{"type":48,"coordinates":152},[153,154],-71.05977,42.35843,{"lat":154,"lon":153},{"facility":40,"status":41,"city":157,"state":158,"zip":159,"country":45,"countryCode":46,"cosmosGeoPoint":160,"geoPoint":164,"contacts":25},"Flowood","Mississippi","39232",{"type":48,"coordinates":161},[162,163],-90.13898,32.30959,{"lat":163,"lon":162},{"facility":40,"status":41,"city":166,"state":167,"zip":168,"country":45,"countryCode":46,"cosmosGeoPoint":169,"geoPoint":173,"contacts":25},"Cedarhurst","New York","11516",{"type":48,"coordinates":170},[171,172],-73.7243,40.62288,{"lat":172,"lon":171},{"facility":40,"status":41,"city":167,"state":167,"zip":175,"country":45,"countryCode":46,"cosmosGeoPoint":176,"geoPoint":180,"contacts":25},"10029",{"type":48,"coordinates":177},[178,179],-74.00597,40.71427,{"lat":179,"lon":178},{"facility":40,"status":41,"city":167,"state":167,"zip":182,"country":45,"countryCode":46,"cosmosGeoPoint":183,"geoPoint":185,"contacts":25},"10036",{"type":48,"coordinates":184},[178,179],{"lat":179,"lon":178},{"facility":40,"status":41,"city":187,"state":167,"zip":188,"country":45,"countryCode":46,"cosmosGeoPoint":189,"geoPoint":193,"contacts":25},"The Bronx","10461",{"type":48,"coordinates":190},[191,192],-73.86641,40.84985,{"lat":192,"lon":191},{"facility":40,"status":41,"city":195,"state":196,"zip":197,"country":45,"countryCode":46,"cosmosGeoPoint":198,"geoPoint":202,"contacts":25},"Bellevue","Washington","98007",{"type":48,"coordinates":199},[200,201],-122.20068,47.61038,{"lat":201,"lon":200},{"type":204,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100610456","phase-3-efficacy-of-nbi-1117568-in-preventing-relapse-in-adults-with-schizophrenia-100610456",false,"NCT07227818","Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia","A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia","Key Inclusion Criteria:\n\n* Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria.\n* Participant had the initial diagnosis of schizophrenia ≥1 year before screening.\n* Participant has had a positive response to ≥1 antipsychotic therapy (other than clozapine) at a therapeutic dose.\n\nKey Exclusion Criteria:\n\n* Participant has an unstable or poorly controlled medical condition or chronic disease (including history of neurological \\[including dementing illness, myasthenia gravis\\], hepatic, renal, cardiovascular, gastrointestinal, pulmonary, autoimmune, or endocrine disease that may affect study participation or results) or malignancy within 30 days before Day 1.\n* Participant has any laboratory abnormalities suggestive of clinically significant, poorly managed, or unmanaged undiagnosed disease.\n* Participant has a history of clozapine treatment for treatment-resistant psychosis.\n* Participant has a history of a stay in a psychiatric inpatient facility for ≥30 consecutive days (other than for purely social reasons or due to participation in a different clinical trial) during the 90 days before screening.\n* Participant has initiated or increased intensity of nonpharmacological psychosocial therapeutic treatment within 3 weeks before screening or is expected to change throughout the length of the study.\n\nNote: Other protocol-defined Inclusion and Exclusion criteria may apply.","ALL","18 Years","65 Years",{"count":216,"type":217},560,"ESTIMATED","INTERVENTIONAL",[220],"PHASE3","The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.",[223],"Schizophrenia",[223,9],"2026-06-04",{"date":227,"type":228},"2026-06-05","ACTUAL",{"date":230,"type":228},"2025-12-16",{"date":232,"type":217},"2029-07",{"name":5,"class":6},20]